MIRD Dose Estimate Report No. 20: Radiation Absorbed-Dose Estimates for ¹¹¹In- and ⁹⁰Y-Ibritumomab Tiuxetan

¹ Radioisotopes Program, Pacific Northwest National Laboratory, Richland, Washington
² Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama

^* To whom correspondence should be addressed. E-mail: dr.fisher{at}pnl.gov.

	Abstract

Absorbed-dose calculations provide a scientific basis for evaluating the biologic effects associated with administered radiopharmaceuticals. In cancer therapy, radiation dosimetry supports treatment planning, dose-response analyses, predictions of therapy effectiveness, and completeness of patient medical records. In this study, we evaluated the organ radiation absorbed doses from intravenously administered ¹¹¹In- and ⁹⁰Y-ibritumomab tiuxetan. Methods: Ten patients (6 men and 4 women) with non-Hodgkin lymphoma, cared for at 3 different medical centers, were administered the tracer ¹¹¹In-ibritumomab tiuxetan and assessed using planar scintillation camera imaging at 5 time points and CT–organ volumetrics to determine patient-specific organ biokinetics and dosimetry. Explicit attenuation correction based on the transmission scan or transmission measurements provided the fraction of ¹¹¹In-administered activity in 7 major organs, the whole body, and remainder tissues over time through complete decay. Time–activity curves were constructed, and radiation doses were calculated using MIRD methods and implementing software. Results: Mean radiation absorbed doses for ¹¹¹In- and for ⁹⁰Y-ibritumomab tiuxetan administered to 10 cancer patients are reported for 24 organs and the whole body. Biologic uptake and retention data are given for 7 major source organs, remainder tissues, and the whole body. Median absorbed dose values calculated by this method were compared with previously published dosimetry for ibritumomab tiuxetan and the product package insert. Conclusion: In high-dose radioimmunotherapy, the importance of patient-specific dosimetry becomes obvious when the objective of treatment planning is to achieve disease cures, safely, by limiting radiation dose to any critical normal organ to its maximum tolerable value. Compared with the current package insert, we found differences in median absorbed dose by multiples of 24 in the kidneys, 1.8 in the red marrow, 0.65 in the liver, 0.077 in the intestinal wall, 0.30 in the lungs, 0.46 in the spleen, and 0.34 in the heart wall.

Key Words: ⁹⁰Y-ibritumomab tiuxetan, Zevalin, ¹¹¹In-ibritumomab tiuxetan, MIRD dose estimate report, lymphoma, dosimetry, antibody, radiopharmaceutical

This article has been cited by other articles:

				S. Shen, A. Forero, R. F. Meredith, J. J. Shah, S. J. Knox, G. A. Wiseman, M. E. Usrey, and A. F. LoBuglio Impact of Rituximab Treatment on 90Y-Ibritumomab Dosimetry for Patients with Non-Hodgkin Lymphoma J. Nucl. Med., January 1, 2010; 51(1): 150 - 157. [Abstract] [Full Text] [PDF]

				A. B. Delaloye, C. Antonescu, T. Louton, J. Kuhlmann, and A. Hagenbeek Dosimetry of 90Y-Ibritumomab Tiuxetan as Consolidation of First Remission in Advanced-Stage Follicular Lymphoma: Results from the International Phase 3 First-Line Indolent Trial J. Nucl. Med., November 1, 2009; 50(11): 1837 - 1843. [Abstract] [Full Text] [PDF]